# LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
> **NDA207315** · New Drug Application · Sponsor: HETERO LABS LTD III · Approved 2017-05-05
## Drug
- **FDA Application Number:** NDA207315
- **Application type:** New Drug Application
- **Brand name:** LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
- **Generic name:** Lamivudine
- **Active ingredients:** LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** HETERO LABS LTD III
- **First approval:** 2017-05-05
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207315)
---
*MORVS · CC0 1.0*